Eden Re II Ltd.

The Artemis Catastrophe Bond and Insurance-linked Securities Deal Directory aims to provide a one-stop resource for information on every cat bond and ILS transaction we hold information on. The content of this Deal Directory is provided as is and there will be some omissions. Help us to keep these cat bond and ILS transaction summaries up to date by contacting us if you see an error or omission that you can correct.

Share

Eden Re II Ltd. sidecar snapshot

  • Reinsurance sidecar: Eden Re II Ltd.
  • Sponsor: Munich Re
  • Launched: December 2014
  • Latest size: $290m (as at December 2014)

Eden Re II Ltd. sidecar details

In late December 2014 one of the world’s leading reinsurers, Munich Re, launched Eden Re II Ltd., a $290m fully-collateralized reinsurance sidecar vehicle, listed on the Bermuda Stock Exchange (BSX). The $290m of participating notes in the reinsurance sidecar facility were split into $242m of participating notes without voting rights, and another $42m of participating notes that do have voting rights. All of the notes have a due date of April 19th, 2018.

Shortly after the launch of Eden Re II Ltd. Munich Re Board Member, Thomas Blunck commented on the sidecar; “This sidecar transaction provides a basis to create synergies between large institutional investors’ interest in reinsurance risk and our core business of covering the Nat Cat risk of our clients.”

Munich Re’s first sidecar vehicle issuance under the Eden Re naming convention, Eden Re Ltd., launched on January 3rd 2014, with a total capital size of $63m.

January 2015 also saw Munich Re issue a $75m fully-collateralized reinsurance sidecar, Eden Re I Ltd. (Series 2015-1).

Go back to the Artemis Collateralized Reinsurance Sidecar Directory.

———————————————————————
Survey imageAlongside our sister publication Reinsurance News, we’ve launched a new survey for the insurance, reinsurance and insurance-linked securities (ILS) industry, asking for your opinion on the market implications of the Covid-19 coronavirus pandemic. Answer our survey here.

Read Covid-19 coronavirus related news & analysis here.